Back
75· Active
Health & Science3h 13m ago
The FDA has granted expanded approval for Elevidys, the first gene therapy for Duchenne muscular dystrophy, to include children aged four and older regardless of ambulatory status.
Silver Spring, Maryland, USA
Who
U.S. Food and Drug Administration (FDA) / Sarepta Therapeutics
What
The FDA has granted expanded approval for Elevidys, the first gene therapy for Duchenne muscular dystrophy, to include children aged four and older regardless of ambulatory status.
When
Wed, 10 Jun 2026 07:00:12 GMT · 3h 13m ago
Where
Silver Spring, Maryland, USA · 39.00°N, 77.03°W
Why
The decision follows clinical data suggesting the therapy's potential to slow disease progression in a broader patient population than previously authorized.
The Frontline Impact
How this affects you
This significantly widens access to a life-changing genetic treatment for families managing DMD, though the high cost of therapy remains a hurdle for healthcare providers and insurers.
Story chain
1 event in this threadNo related history yet — this is the origin event.
Verified Sources & Citations
Credibility ratings reflect the AI ingestion pipeline's assessment of source provenance.